We are live on ! Find out more
JO

John Overdeck Two Sigma Investments

AUM $138B
1-Year Est. Return 41.87%
 

John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.

This Fund
S&P 500
This Quarter Est. Return
-16.78%
1 Year Est. Return
+41.87%
3 Year Est. Return
+122.61%
5 Year Est. Return
+129.48%
10 Year Est. Return
+649.67%
AUM
$25.5B
AUM Growth
-$11.1B
Cap. Flow
-$5.25B
Cap. Flow %
-20.57%
Top 10 Hldgs %
6.83%
Holding
3,851
New
729
Increased
952
Reduced
1,216
Closed
943

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 15.51%
2 Technology 14.81%
3 Industrials 12.21%
4 Healthcare 10.11%
5 Financials 6.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
DWSN icon
2876
Dawson Geophysical
DWSN
$103M
$35K ﹤0.01%
+10,361
New +$49.2K
TRIL
2877
DELISTED
Trillium Therapeutics Inc.
TRIL
$35K ﹤0.01%
+20,300
New +$60.9K
NEOS
2878
DELISTED
Neos Therapeutics, Inc
NEOS
$35K ﹤0.01%
+21,249
New +$59.6K
CARM
2879
DELISTED
Carisma Therapeutics
CARM
$34K ﹤0.01%
+1,212
New +$38.7K
BW icon
2880
Babcock & Wilcox
BW
$1.17B
$31K ﹤0.01%
7,861
-6,972
-47% -$62K
ARTX
2881
DELISTED
Arotech Corporation
ARTX
$30K ﹤0.01%
11,377
-7,100
-38% -$19.9K
CEI
2882
DELISTED
Camber Energy, Inc
CEI
0
FBIO icon
2883
Fortress Biotech
FBIO
$94.4M
$27K ﹤0.01%
2,064
+1,014
+97% +$16.9K
ALT icon
2884
Altimmune
ALT
$622M
$26K ﹤0.01%
+12,481
New +$44.2K
SND icon
2885
Smart Sand
SND
$199M
$25K ﹤0.01%
+11,351
New +$35.8K
TANH icon
2886
Tantech Holdings
TANH
$5.5M
$24K ﹤0.01%
+1
New +$16.2K
EYPT icon
2887
EyePoint Inc
EYPT
$431M
$21K ﹤0.01%
+1,090
New +$26.4K
RGLS
2888
DELISTED
Regulus Therapeutics
RGLS
$21K ﹤0.01%
+2,222
New +$36.8K
ZVRA icon
2889
Zevra Therapeutics
ZVRA
$715M
$19K ﹤0.01%
+681
New +$27.6K
QTRH
2890
DELISTED
Quarterhill Inc. Common Shares
QTRH
$19K ﹤0.01%
+19,604
New +$22.4K
ALTO icon
2891
Alto Ingredients
ALTO
$309M
$18K ﹤0.01%
+21,419
New +$35.4K
SPHS
2892
DELISTED
Sophiris Bio, Inc.
SPHS
$17K ﹤0.01%
+20,320
New +$40K
AEHL icon
2893
Antelope Enterprise Holdings
AEHL
$6.97M
0
VIRX
2894
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$15K ﹤0.01%
1,032
-1,034
-50% -$42.2K
HOS
2895
DELISTED
Hornbeck Offshore Services, Inc.
HOS
$15K ﹤0.01%
+10,639
New +$37.3K
APVO icon
2896
Aptevo Therapeutics
APVO
$4.43M
0
MR
2897
DELISTED
Montage Resources Corporation Common Stock
MR
$12K ﹤0.01%
754
-3,323
-82% -$56.8K
NM
2898
DELISTED
Navios Maritime Holdings Inc.
NM
$11K ﹤0.01%
+3,953
New +$17.5K
OMED
2899
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$11K ﹤0.01%
14,738
-8,200
-36% -$12.3K
DNN icon
2900
Denison Mines
DNN
$3.37B
$7K ﹤0.01%
+15,597
New +$8.9K

Similar funds

John Overdeck's Q4 2018 Portfolio in Review

As of Q4 2018, John Overdeck held 3,851 positions worth $25.5B, down 30% from $36.7B the previous quarter. Its ten largest holdings account for 6.8% of the portfolio.

John Overdeck withdrew a net $5.25B in Q4 2018, closing 943 positions and reducing 1,216 holdings. Its most notable exit was Elevance Health, an estimated $180M position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 16% of assets, up from 13% a quarter earlier, followed by Technology and Industrials.

Against the trend, John Overdeck opened a new position in Starbucks worth $176M.

  • John Overdeck's largest Q4 2018 buy was Starbucks: 2,727,875 shares worth $176M.
  • John Overdeck added most to SLB Ltd in Q4 2018, an estimated $230M increase.
  • John Overdeck's biggest Q4 2018 reduction was Procter & Gamble, cutting an estimated $185M.
  • John Overdeck fully exited Elevance Health in Q4 2018, selling an estimated $180M.
  • John Overdeck's ten largest holdings make up 6.8% of its $25.5B portfolio in Q4 2018.
  • John Overdeck opened 729 new positions and closed 943 in Q4 2018.
  • John Overdeck's portfolio value fell 30% quarter-over-quarter to $25.5B.

Based on Two Sigma Investments's 13F filing for Q4 2018, filed 14 Feb 2019.